Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2016 3
2017 1
2018 6
2019 3
2020 6
2021 12
2022 12
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Among authors: ansstas g. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
PARP inhibition and immunotherapy: a promising duo in fighting cancer.
Phillipps J, Zhou AY, Butt OH, Ansstas G. Phillipps J, et al. Among authors: ansstas g. Transl Cancer Res. 2023 Sep 30;12(9):2433-2437. doi: 10.21037/tcr-23-726. Epub 2023 Aug 3. Transl Cancer Res. 2023. PMID: 37859734 Free PMC article. No abstract available.
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA, Morecroft R, Phillipps J, Adeyelu T, Elliott A, Park SJ, Butt OH, Zhou AY, Ansstas G. Akinjiyan FA, et al. Among authors: ansstas g. Int J Mol Sci. 2023 Jun 28;24(13):10771. doi: 10.3390/ijms241310771. Int J Mol Sci. 2023. PMID: 37445949 Free PMC article. Review.
Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.
Khaddour K, Dowling J, Huang J, Council M, Chen D, Cornelius L, Johanns T, Dahiya S, Ansstas G. Khaddour K, et al. Among authors: ansstas g. Oncotarget. 2023 Feb 11;14:126. doi: 10.18632/oncotarget.28365. Oncotarget. 2023. PMID: 36780317 Free PMC article. No abstract available.
49 results